• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:06:54 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    clov-20250506
    FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702025-05-062025-05-06

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

    CLOVER HEALTH INVESTMENTS, CORP.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware
    001-3925298-1515192
    (State or Other Jurisdiction
    (Commission File Number)
    (IRS Employer
    of Incorporation)
    Identification No.)
    Not Applicable(1)
     Not Applicable(1)
    (Address of Principal Executive Offices)(Zip Code)
    Not Applicable(1)
    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


    Securities registered pursuant to Section 12(b) of the Act:

    Trading
    Title of each class
    Symbol(s)
    Name of each exchange on which registered
    Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    (1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: [email protected], or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.





    Item 2.02 Results of Operations and Financial Condition.
    On May 6, 2025, Clover Health Investments, Corp. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
    The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
    Item 9.01. Financial Statements and Exhibits.

    (d) List of Exhibits

    Exhibit No.Description
    99.1
    Press release dated May 6, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)





    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


    Clover Health Investments, Corp.
    Date:May 6, 2025By:/s/ Peter Kuipers
    Name:Peter Kuipers
    Title:Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

    Get the next $CLOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings